Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with 67Cu.

Abstract

Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 × 15 MBq, 2 wk apart) administrations. Conclusion:67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.

• Authors: Lachlan E McInnes, Carleen Cullinane, Peter D Roselt, Susan Jackson, Benjamin J Blyth, Ellen M van Dam, Nicholas A Zia, Matthew J Harris, Rodney J Hicks, Paul S Donnelly
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 62 Issue 6 Pg. 829-832 (06 01 2021) ISSN: 1535-5667 [Electronic] United States
• PMID: 33067341 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Chemical References

• Antigens, Surface
• Copper Radioisotopes
• Copper-67
• FOLH1 protein, human
• Glutamate Carboxypeptidase II

Topics

• Animals
• Antigens, Surface (chemistry)
• Cell Line, Tumor
• Cell Transformation, Neoplastic
• Copper Radioisotopes (chemistry)
• Glutamate Carboxypeptidase II (chemistry)
• Isotope Labeling
• Male
• Prostatic Neoplasms (pathology)